澳大利亚Biota 
澳洲药品开发商Biota宣布其日本伙伴公司已成功研制一种新的抗病毒药物，仅需一剂即可对抗流感，它在亚洲市场的初步实验获得成功。
　　药品laninamivir对流感具有快速有效的作用，它可能接替瑞沙（Relenza）、达菲（Tamiflu），成为流感的主要药物。新药物需要每天服用，可治疗甲流感，也可预防流感。
　　Biota主管库克（Peter Cook）表示，该药物将在不久后启动商业供应，它在日本、台湾、香港和韩国进行的测试显示药物安全且有效。临床实验的对象有成人也有儿童，只需一个剂量即可消除流感的隐患，而使用达菲则需要每天两次，总计5天。新药物对儿童摆脱流感威胁的效果尤为明显，远超达菲。
　　Biota的合作伙伴公司Daiichi Sankyo已向日本当局提出申请，计划在明年让药物上市。之后，该药物将寻求美国和澳洲市场的认可，在这段时间里，它将完成更多的试验，来保证药物的安全性。
　　库克表示，新药物只需一剂量就可有效对抗季节性流感、禽流感和甲流感。与瑞沙一样，新药物需要一种吸入设备，并对儿童的使用存在一些限制。
　　昨日，英国医学杂志（British medical journal－BMJ）发表的一篇新研究表示，
　　儿童患季节性流感不应给予抗病毒药物，因为相比它的微小作用，药物将对儿童产生巨大的副作用。临床实验发生，一些服用达菲后的儿童，出现恶心和呕吐的副作用，甚者还出现脱水和其他并发症。
　　研究人员表示，这项研究并沒有特别针对目前全面爆发的甲流感，临床实验结果证明，对于感染了新H1N1A型流感的儿童而言，新药laninamivir收效甚微。

Biota is a leading anti-infective drug development company, based in Melbourne, Australia and Oxford, UK.

Biota's initial success was the discovery of zanamivir, the first-in-class neuraminidase inhibitor for the treatment and prevention of influenza. Zanamivir is licensed to GlaxoSmithKline and marketed as Relenza™. Relenza is used to treat seasonal influenza and is currently being stockpiled by various governments for defence against possible pandemic outbreaks of influenza.

Biota also has key partnerships with:

Boehringer Ingelheim: where it has a licence and collaboration agreement to develop and commercialise Biota's novel nucleoside analogues, designed to treat hepatitis C virus (HCV) infections and potentially other diseases.
Daiichi Sankyo: for the development of second generation influenza antivirals (called LANI or long-acting inhaled neuraminidase inhibitors).
In 2009:

Phase IIa clincial trials of its lead human rhinovirus (HRV) drug achieved clinical proof-of-concept. The drug is aimed at prevention and treatment of one of the major causes of the common cold which is also throught to be a major cause of exacerbations in patients with chronic obstructive pulmonary disease and asthma.
Phase III trials for laninamivir in Asia were shown to be effective. Daiichi Sankyo, who co-own the LANI program have elected to market the drug in Japan.
Biota expanded its antibacterial interests following the asset acquisitions of Prolysis Limited and MaxThera Inc.
The Company's research pipeline includes other earlier stage, small molecule anti-infective programs focused on diseases of significant medical need, such as hepatitis C, respiratory syncytial virus, human cytomegalovirus and new classes of DNA antibiotics to treat hospital-acquired and community-associated infections.

Biota is listed on the Australian Stock Exchange (ASX:BTA).